Independent equity research on quality micro and small-cap businesses — the ones built to compound for a decade before the world catches on. Read by 12,400+ investors.
We invest behind durable advantages, strong cash flow, and visible growth runways. The math has to work before we write a word.
Most analysts cover the same 500 names. We work the long tail — micro and small caps the algorithms haven't found yet.
No banking relationships. No paid placements without disclosure. We hold positions in many names we cover — and we tell you when we do.
Our latest long-form report — built to outlast the news cycle.
Biotech capital in 2026 has demonstrated unusual appetite at the intersection of cardiology and inflammatory pathways. We trace the deal flow, the underlying science, and the small handful of companies positioned at the front of the wave.
We don't chase narrative — we measure it. Every report follows the same four-stage process, refined over hundreds of company conversations.
Read about our approach →We start with the long tail — companies under $1B that pass our quality screens for growth, margins, and capital efficiency.
Before the model, the call. We interview operators, customers, suppliers, and competitors. The argument is built from people.
Three-statement model from scratch. Unit economics, capital allocation history, and the footnotes the bankers hope you'll skip.
Reports go out only when the work is finished. We disclose our positions, then update readers as the thesis develops.
Filter by sector, or browse the full archive. New research every 2–3 weeks.
While headlines track oil prices and missile strikes, a $1.8T private credit market is quietly approaching its first stress test under fire.
The past quarter has reminded the market that commodities, too, can compound. We examine which second-order plays capture the move.
Decades of underinvestment in domestic supply have created an opportunity hidden in plain sight. A long read on a junior worth knowing.
A post-mortem on a category leader that lost its moat. The deeper I dug, the more I realized only one of these was still a business.
"The stock is not the company, the company is not the stock." A close read of one of the more curious benchmark results of the year.
"I don't look to jump over 7-foot bars: I look around for 1-foot bars that I can step over." A study in capital discipline applied.
One rigorous research note, delivered every Sunday. No filler. No sponsored content. Just data-driven small-cap analysis for serious investors.
